Groundbreaking Dual-Action Therapy CG-0416 Revolutionizes Obesity Management at 2025 EASL Congress At the 2025 EASL Congress, CureGene Pharmaceuticals revealed CG-0416, a pioneering dual-action therapy targeting obesity and liver health with remarkable efficacy.

Groundbreaking Dual-Action Therapy CG-0416 Revolutionizes Obesity Management at 2025 EASL Congress #China #Shanghai #CureGene #EASL_Congress #CG-0416

AusperBio Showcases Promising Clinical Data for AHB-137 During EASL Congress 2025 AusperBio Therapeutics presents significant interim data for AHB-137 at the EASL Congress 2025, spotlighting its potential in hepatitis B treatment.

AusperBio Showcases Promising Clinical Data for AHB-137 During EASL Congress 2025 #United_States #San_Francisco #AusperBio #AHB-137 #EASL_Congress

MetaVia Inc. to Present Late-Breaking Data on DA-1241 at EASL Congress 2025 MetaVia Inc. will unveil data from its Phase 2a trial on DA-1241, a novel treatment for metabolic diseases, at the EASL Congress 2025 in Amsterdam.

MetaVia Inc. to Present Late-Breaking Data on DA-1241 at EASL Congress 2025 #USA #Cambridge #MetaVia #DA-1241 #EASL_Congress